The case against Caremark, Express Scripts, and Optum Rx is the first against this element of the pharmaceutical transaction chain.
PBMs
Posted inEconomic Policy
Small-Business Regulators Highlight Protection From Predation
Contrary to the discussion at the presidential level, small businesses are seeking access to credit and a level playing field for their enterprises.
Posted inHealth and Social Policy
The Bipartisan Reform Opportunity Staring Kamala Harris in the Face
Both parties want to crack down on pharmacy benefit managers. The vice president could help get it done.
Posted inTAP
FTC Comes for PBMs
Today on TAP: An interim report shows how pharmaceutical middlemen raise drug prices and damage care.
Posted inHealth and Social Policy
New Bill Seeks to End Drug Shortages
The Senate Finance Committee wants to create a new program to incentivize better practices. Critics say there’s an easier way: end kickbacks between suppliers and bulk purchasers.
Posted inHealth and Social Policy
Our Uniquely American Drug Shortages
More drugs are in short supply than ever before. We’ve known the reason why for a long time: monopolistic middlemen.
Posted inHealth and Social Policy
The PBM-Insurer Mafia Comes for Community Pharmacies
UnitedHealth, CVS, and Cigna’s PBMs are using their market share and pull in Washington to drive one of the key levers to manage health care costs—independent pharmacies—out of business.
Posted inHealth and Social Policy
Zoomer Hackers Shut Down the Biggest Extortion Ring of All
A ransomware gang cripples UnitedHealthcare. Could a comprehensive antitrust investigation finish the job?
Posted inHealth and Social Policy
Public Pharma’s Biggest Barrier
California is about to start developing and manufacturing insulin. But is the state too tied up with nonprofit Civica Rx, rather than building its own capacity?